



Next Target for Valve Pharmacology: Mechanical Valve Revisited with NOAC

RENOVATE Trial

Joon Bum Kim, MD, PhD

Dept. Thoracic and Cardiovascular Surgery Asan Medical Center University of Ulsan College of Medicine





Thrombo-embolism

Hemorrhage

Valve reoperation





NHIS Database, AVR

Between 2003 and 2018


Age: 40-80yrs

N = 15,726







Adjusted Survival in AVR: <55yrs



Adjusted Survival in AVR: 55~64yrs



Adjusted Survival in AVR: ≥65yrs




Presented in 2022 AATS, under peer review





Age-Dependent Adjusted Survival in AVR




Presented in 2022 AATS, under peer review






Bio and Mechanical AVR: All age 2000-2020 AMC







Bio and Mechanical AVR: Age >=60, <70 yrs



rear



Living With Warfarin


"I feel my whole life is controlled by warfarin"

-www.afa.org.uk-

- Regular **blood test** at least once a 12 weeks: even shorter in fluctuating INR
- Don't make changes to your **diet or alcohol intake** consistency is the key
 - Green leafy vegetables
 - Eat same amount of these foods each week to help keep your INR stable
- Check before starting a **new medicine**
- Take precautions to prevent injuries














Trends in AMC



2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021

TAVR SAVR






What if





Non-Vit K Oral Anticoagulant



Fixed doses qd or bid
No food/ alcohol restriction
No blood testing
Fast onset / clearance
Lower bleeding risks proven in AF
Comparable efficacy proven in AF

Reproducible in mechanical heart valves?





The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Dabigatran versus Warfarin in Patients with Mechanical Heart Valves


John W. Eikelboom, M.D., Stuart J. Connolly, M.D., Martina Brueckmann, M.D., Christopher B. Granger, M.D., Arie P. Kappetein, M.D., Ph.D., Michael J. Mack, M.D., Jon Blatchford, C.Stat., Kevin Devenny, B.Sc., Jeffrey Friedman, M.D., Kelly Guiver, M.Sc., Ruth Harper, Ph.D., Yasser Khder, M.D., Maximilian T. Lobmeyer, Ph.D., Hugo Maas, Ph.D., Jens-Uwe Voigt, M.D., Maarten L. Simoons, M.D., and Frans Van de Werf, M.D., Ph.D., for the RE-ALIGN Investigators*

ABSTRACT

N Engl J Med 2013;369:1206-14.

The NEW ENGLAND JOURNAL of MEDICINE

UNIVERSITY OF ULSAN COLLEGE OF MEDICINE



BACKGROUND

ASAN


Medical Center





OF ULSAN

Factor X:



Noel C. Chan et al. Arterioscler Thromb Vasc Biol. 2017;37:743-745.





Lesson from the Re-Align Trial:

2. Dose Escalation

Table 2. Patients Requiring Dose Escalation or Discontinuation of Dabigatran and Mean Percentage of Time above the Target Trough Plasma Level of Dabigatran.*

Dabigatran Dose	Population A (N=127)		Population B (N=35)		All Patients (N=162)	
	Patients Requiring Dose Escalation or Discontinuation† no./total no. (%)	Percent of Time above Target Level‡	Patients Requiring Dose Escalation or Discontinuation† no./total no. (%)		Patients Requiring Dose Escalation or Discontinuation† no./total no. (%)	
All doses	47/127 (37)	84	5/35 (14)	96	52/162 (32)	86
150 mg twice daily	4 /11 (36)	99	2/13 (15)	98	6/24 (25)	98
220 mg twice daily	32/71 (45)	84	1/16 (6)	100	33 /87 (38)	87
300 mg twice daily	11/45 (24)	79	2/6 (33)	83	13/51 (25)	79

Target blood concentration: >50ng/mL






Lesson from the Re-Align Trial: 3. Timing of Medication

RE-ALIGN: results Stroke Bleeding Death Systemic MI embolism Any Major 2 Warfarin 2 0 0 0 8 (3%) (12%) (3%) n=66 Population A 35 0 7 **Dabigatran** 9 (1%)(7%) (26%) (5%) (1%)n=133 trial stopped Warfarin 0 0 2 0 (11%) n=18 Population B 0 10 0 0 Dabigatran (29%)(6%)n=35 B: surgery A: Mean FU duration: (>3 surgery Population A: - warfarin arm: 152 days months) aortic - dabigatran arm: 143 days and/or mitral Population B: - warfarin arm: 143 days mitral (±aortic) - dabigatran arm: 136 days





Lesson from the Re-Align Trial: 3. *Timing of Medication*







Lesson from the Re-Align Trial: 4. Valve Position

Table 1. Baseline Characteristics of the Patients.*				
Characteristic	Dabigatran (N=168)	Warfarin (N=84)		
Type of valve-replacement surgery –	– no. (%)			
Aortic	113 (67)	59 (70)		
Mitral	49 (29)	22 (26)		
Aortic and mitral	6 (4)	3 (4)		







NOAC for Mechanical Heart Valve


	More likely to be effective	Less likely to be effective	
Time from surgery	>3 months	<3 months	
Position	Aortic	Mitral/right heart valve	
Systolic function	Preserved	Reduced	
Bleeding risk	Low	Intermediate-high	
Hypercoagulability	No	Yes	
Compliance to therapy	Good	Poor	

Circulation. 2018;138:1356-1365.



PROACT Xa Trial





2 year follow-up

Primary endpoint: composite of valve thrombosis, valve-related thromboembolism, valve thrombosis related mortality

Secondary endpoints: components of primary composite endpoint, major bleeding

Study Chair: Lars Svensson, MD, PhD and John Alexander, MD





RENOVATE Trial

Randomized Evaluation of LoNg-term Anticoagulation with Oral Factor Xa Inhibitor versus Vitamin K Antagonist after Mechanical AorTic Valve ReplacEment





<u>Randomized Evaluation of LoNg-term Anticoagulation with Oral Factor Xa Inhibitor</u> <u>versus Vitamin K Antagonist after Mechanical AorTic Valve REplacement</u>

RENOVATE Trial

1,300 Patients with Mechanical Aortic Valve Replacement at least 3 months after Operation

Stratified randomization by (1) atrial fibrillation and (2) participating site

Oral Factor Xa Inhibitor Rivaroxaban 20mg QD (N=650)



Vitamin K Antagonist INR 2.0 ~ 3.0 (N=650)

Primary endpoint: a composite of cardiac death, valve thrombosis, valve-related thromboembolic event, major bleeding, and clinically-relevant non-major bleeding (BARC 2,3, or 5) at 12 months





Sample Size

- Non-inferiority trial design
- % of primary endpoint: 15.0% in the WARF group based on results from ENGAGE AF-TIMI 48, RE-LY, and ROCKET AF trials
 - Death: 1.76%; Thromboembolism: 1.75%; Major bleeding: 3.63%; Non-major bleeding: 8%
- Non-inferiority margin: 5.0% (1/3 of 15.0%)
- Dropout rate: 3%
- Power=80%; Alpha-level=0.05
- Final N=1300 (650 vs. 650)







- Multi-center, randomized, open-label trial
- Randomization: stratified by the presence of AF and participating sites

- Interventions:
- **Rivaroxaban Group:**
 - Rivaroxaban oral tablet 20mg once daily
 - Creatinine clearance 15-49 mL/min, 15mg once daily
- Warfarin Group:
 - Target INR of 2.0-3.0





Secondary Endpoint

- All-cause death
- Individual components of primary endpoint
- Valve thrombosis confirmed by echocardiography, cine fluoroscopy, CT or autopsy
- Transient ischemic attack
- Myocardial infarction
- Echocardiographic parameters (max/mean PG, EOA) at 1 year





Inclusion criteria

- 1. Age 19 yrs and more
- 2. At least 3months after mechanical SAVR
- 3. NYHA Fc I or II
- 4. Mean AV gradient <20 mm Hg or peak velocity <3 m/s,
 - AND no moderate or severe prosthetic valve regurgitation
- 5. Voluntarily participated in the written agreement





- 1. Old generation mechanical valve
- 2. History of mechanical valve implantation in the MV, PV or TV
- 3. Valvular atrial fibrillation (moderate or severe MS)
- 4. Moderate to severe mitral stenosis
- 5. History of hemorrhagic stroke
- 6. Clinically overt stroke within the last 3 months
- 7. Renal failure(creatinine clearance <15mL/min) or on hemodialysis
- 8. Left ventricular dysfunction: LVEF ≤40%
- 9. Hepatic impairment, or severe (Child-Pugh C) or with any hepatic disease associated with coagulopathy





- 10. Clinically significant active bleeding
- 11. Bleeding or hemorrhagic disorder

12. The increased risk of bleeding

- a. History of gastrointestinal ulcers or active ulcerations within the last 6 months
- b. History of intracranial or intracerebral hemorrhage within the last 6 months
- c. Spinal cord vascular abnormalities or intracerebral vascular abnormalities
- d. History of the brain, spinal cord, or ophthalmic surgery within the last 6 months
- e. History of the brain or spinal cord injury within the last 6 months
- f. History of spinal tap, major regional anesthesia or, spinal anesthesia within the last 6 months
- g. Esophageal varices
- h. Arteriovenous malformation
- i. Vascular aneurysms
- j. Malignant tumor with a high risk of bleeding





13. Bleeding tendencies associated with overt bleeding of

- a. gastrointestinal, genitourinary, respiratory tract or, colorectal cancer
- b. cerebrovascular hemorrhage
- c. aneurysms- cerebral, dissecting aorta
- d. pericarditis and pericardial effusions
- e. bacterial endocarditis

14. Hemodynamically unstable pulmonary embolism
15. Combination therapy with other anticoagulants
16. Uncontrolled moderate or severe hypertension
17. Hemoglobin level <10.0 g/dL or platelet count < 100 x 10x9/L
18. Infective endocarditis





19. Hypersensitivity to Rivaroxaban or Vit K antagonist 20. Positive pregnancy test results, threatened abortion 21. Galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption 22. Terminal illness with life expectancy <12 months 23. Vitamin K deficiency 24. Alcoholic or psychical disorder 25. Concomitant use with antiplatelet due to history stroke, TIA or ACS







ated

eding

Randomized Evaluation of LoNg-term Anticoagulation with Oral Factor Xa hibitor versus Vitamin K Antagonist after Mechanical AorTic Valve REplacement

RENOVATE Trial

Participating Centers

1. Asan Medical Center

1.300

Strat

Oral F

Rivar

Primary


thromboe

- 2. Bucheon Sejong Hospital
- 3. Pusan National University Yangsan Hospital
- 4. Yonsei UniversitySeverance Hospital
- 5. Seoul National University Hospital
- 6. Samsung Medical Center
- 7. Gangneung Asan Medical Center
- 8. Korea University Anam Hospital
- 9. Chonnam National University Hospital
- 10. Chungnam National University Hospital
- 11. Keimyong University Dong San Hospital
- 12. Ulsan University Hospital






Age-Dependent Adjusted Survival in AVR







Age-Dependent Adjusted Survival in AVR







Looking forward seeing exciting future